Researcher Information - INAGAKI Ataru |

（Last updated : 2025-03-31 19:30:27）

INAGAKI Ataru

Department / Course

Aoyama Gakuin University College of Education, Psychology and Human Studies Department of Education

Job Professor

Specialization and related fields
Clinical Psychiatry, Pharmacoepidemiology, Pharmacoeconomics

Business career
1.	1992/05 ～ 1994/04	Resident Keio University Hospital Neuropsychiatry
2.	1993/05 ～ 2002/03	Yamanashi Prefectural Kita Hospital Psychiatry
3.	2002/04 ～ 2007/03	Lecturer Keio University Department of Neuropsychiatry, School of Medicine
4.	2006/04 ～ 2007/03	Division director for health insurance Keio University Hospital Department of Neuropsychiatry
5.	2007/04 ～ 2012/03	Project Associate Professor Keio University Graduate School of Health Management
Display All（12）

Belonging society
1.	1993/05 ～	The Japan Society of Psychiatry and Neurology
2.	2007/07 ～	International Society for Pharmacoeconomics and Outcomes Research Japan Chapter
3.	2007/07 ～ 2011/07	∟ Secretary
4.	2007/11 ～	International Society for Pharmacoeconomics and Outcomes Research
5.	2021/12 ～	Japan University Health Administration

Official position and committee in Univ.
1.	2019/04/01 ～ 2021/03/31	Aoyama Gakuin University Associate Director, Healthcare Administration Center
2.	2021/04/01 ～ 2023/03/31	Aoyama Gakuin University Associate Director, Healthcare Administration Center
3.	2022/04/01 ～ 2023/03/31	Aoyama Gakuin University Director, Healthcare Administration Center
4.	2023/04/01 ～ 2025/03/31	Aoyama Gakuin University Associate Director, Healthcare Administration Center
5.	2023/04/01 ～ 2025/03/31	Aoyama Gakuin University Director, Healthcare Administration Center
Display All（8）

Book and thesis
1.	Books	A guide to master the Hamilton Depression Rating Scale: Commentary on the Hamilton Depression Rating Scale (HAMD) and guide to its usage. (Co-authored) 2014/04
2.	Papers	Budget impact analysis of long acting injection for schizophrenia in Japan J Med Econ 23 (8),pp.848-855 (Co-authored) 2020
3.	Papers	Treatment persistence between long-acting injectable versus orally administered aripiprazole among patients with schizophrenia in a real-world clinical setting in Japan Adv Ther 37 (7),pp.3324-3336 (Co-authored) 2020
4.	Papers	101. 稲垣　中: . 32 (4): 354-361, 2018.,pp.354-361 (Sole-authored) 2018/04
5.	Papers	Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method Int J Neuropsychopharmacol 18 (5),pp.1-5 (Co-authored) 2015
Display All（6）